Amendments to the Claims

- 1. (Cancelled)
- 2. (Cancelled)
- (Currently Amended) A compound according to Claim 1Claim 24 wherein X₁ is CH and X₂ is selected CH.
- (Currently Amended) A compound according to Claim 1Claim 24 wherein X₁ is CH and X₂ is selected N.
- 5. (Currently Amended) A compound according to $\frac{Claim + Claim 24}{Claim 34}$ wherein X_1 is N, and X_2 is CH.
- 6. (Currently Amended) A compound according to $\frac{Claim 1}{Claim 24}$ wherein X_1 is N, and X_2 is N.
 - (Cancelled)
 - (Cancelled)
- 9. (Currently Amended) A compound according to $\frac{\text{Claim 2Claim 25}}{\text{CH}}$ wherein X_1 is CH and X_2 is selected CH.
- $10. \qquad \text{(Currently Amended)} \ \ A \ \text{compound according to} \ \ \frac{2\text{Claim} \ 25}{\text{Claim} \ 26} \ \text{wherein} \ X_1$ is CH and X_2 is selected N.
- 11. (Currently Amended) A compound according to $\frac{\text{Claim 2Claim 25}}{\text{Claim 25}}$ wherein X_1 is N, and X, is CH.
- 12. (Currently Amended) A compound according to $\frac{\text{Claim 2Claim 25}}{\text{Claim 25}}$ wherein X_1 is N, and X_2 is N.
 - 13. (Cancelled)

- (Cancelled)
- (Cancelled)
- (Cancelled)
- (Currently Amended) A compound selected from the group consisting of:
- 4-{5-[(3-Methyl-butylamino)-methyl]-indol-1-ylmethyl}-benzamide,
- 4-{5-[(2-Thiophen-2-vl-ethylamino)-methyl]-indol-1-vlmethyl}-benzamide.
- 4-{5-[(3,3-Dimethyl-butylamino)-methyl]-indol-1-ylmethyl}-benzamide,
- 4-{5-[(2-Thiophen-2-yl-ethylamino)-methyl]-2,3-dihydro-indol-1-ylmethyl}-benzamide,
- 4-{5-[(3-Methyl-butylamino)-methyl]-2,3-dihydro-indol-1-ylmethyl}-benzamide,
- 4-{5-[(3,3-Dimethyl-butylamino)-methyl]-2,3-dihydro-indol-1-ylmethyl}-benzamide,
- 4-(5-Hexylaminomethyl-indol-1-ylmethyl)-benzamide.
- 4-{5-[(3-Phenyl-propylamino)-methyl]-indol-1-ylmethyl}-benzamide.
- 4-(5-{[2-(2-Fluoro-phenyl)-ethylamino]-methyl}-indol-1-ylmethyl)-benzamide,
- 4-{5-[(2-Hvdroxy-ethylamino)-methyl]-indol-1-vlmethyl}-benzamide.
- 4-(5-{[2-(4-Methoxy-phenyl)-ethylaminol-methyl}-indol-1-ylmethyl)-benzamide.
- 4-{5-[(2-Chloro-6-fluoro-benzylamino)-methyl]-indol-1-ylmethyl}-benzamide.
- 4-{5-[(2-Pyridin-3-vl-ethylamino)-methyl]-indol-1-vlmethyl}-benzamide.
- 4-(5-{[2-(2-Ethoxy-phenyl)-ethylamino]-methyl}-indol-1-vlmethyl)-benzamide.
- 4-(5-{[2-(Tetrahydro-pyran-4-vl)-ethylaminol-methyl}-indol-1-vlmethyl)-benzamide.
- 4-{5-[(2-Cyclohex-1-envl-ethylamino)-methyl]-indol-1-vlmethyl}-benzamide.
- 4-(5-{[2-(3-Fluoro-phenyl)-ethylamino]-methyl}-indol-1-ylmethyl)-benzamide.
- 4-{5-[(2-Ethyl-butylamino)-methyl]-indol-1-ylmethyl}-benzamide.
- 1-{4-[(3-Methyl-butylamino)-methyl]-benzyl}-2,3-dihydro-1H-indole-5-carboxylic acid amide,
- 1-{4-[(3-Methyl-butylamino)-methyl]-benzyl}-1H-indole-5-carboxylic acid amide, or a pharmaccutically acceptable salt, solvate, enantiomer, diastereomer and diastereomerie mixtureor solvate thereof.
- 18. (Currently Amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I or II or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer or diastereomeric mixture thereof Claim 24 in association with a carrier, diluent and/or excipient.

- 18. (Cancelled)
- 19. (Cancelled)
- 20. (Cancelled)
- 21. (Cancelled)
- 22. (Cancelled)
- 23. (Cancelled)

24. (New) A compound of formula (I)

(I)

wherein:

p is 0, 1, or 2;

y is 0, 1, or 2; and z is 0, 1, or 2;

X₁ is CH₂, CH, or N; to form a indolinyl, indolyl, or benzimidazole ring respectively and including applicable double bonds and/or hydrogen atoms;

X2 is CH or N;

R¹ and R² are independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, 2-methylpentyl, t-butyl, cyclopropyl, phenyl,

$$\begin{array}{c} (\operatorname{CH}_{2,h}) \\ \times (\operatorname{CH$$

each of which is optionally substituted with a group selected from the group consisting of halogen, C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, C_1 - C_8 thioalkyl, C_1 - C_8 alkylamino, phenyl, C_1 - C_8 alkylsubstituted phenyl, C_4 - C_8 heterocycle or C_1 - C_4 alkyl heterocycle;

R3 and R3 are each hydrogen:

 R^4 and R^5 are each independently selected from fluoro, chloro, bromo, methoxy, ethoxy, methyl, ethyl, isopropyl, trifluoromethyl, phenyl and benzyl; wherein each R^4 and R^5 is attached to its respective ring only at carbon atoms; wherein m is 1 or 2; and n is 1, 2, or 3; R^6 and R^7 are each independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl and phenyl;

or a compound selected from the group 4-{5-[(2-Hydroxy-ethylamino)-methyl]-indol-1-ylmethyl}-benzamide; 4-(5-{[2-(4-Methoxy-phenyl)-ethylamino]-methyl}-indol-1-ylmethyl)-benzamide; 4-{5-[(2-Pyridin-3-yl-ethylamino)-methyl]-indol-1-ylmethyl}-benzamide; 4-(5-{[2-(2-Ethoxy-phenyl)-ethylamino]-methyl}-indol-1-ylmethyl)-benzamide; and 4-{5-[(2-Cyclohex-1-enyl-ethylamino)-methyl]-indol-1-ylmethyl}-benzamide; or a pharmaceutically acceptable salt or solvate thereof.

25. (New) A compound of formula II

$$(CR^3R^3)_p$$
 $(R^5)_z$
 $(R^4)_y$
 $(R^4)_y$
 $(R^4)_y$

wherein p is 0, 1, or 2;

y is 0, 1, or 2; and z is 0, 1, or 2;

X₁ is CH₂, CH, or N; to form a indolinyl, indolyl, or benzimidazole ring respectively and including applicable double bonds and/or hydrogen atoms;

X2 is CH or N;

R¹ and R² are independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, 2methylpentyl, t-butyl, cyclopropyl, phenyl,

each of which is optionally substituted with a group selected from the group consisting of halogen, C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, C_1 - C_8 thioalkyl, C_1 - C_8 alkylamino, phenyl, C_1 - C_8 alkylsubstituted phenyl, C_4 - C_8 heterocycle or C_1 - C_4 alkyl heterocycle;

R3 and R3 are each hydrogen;

 R^4 and R^5 are each independently selected from fluoro, chloro, bromo, methoxy, ethoxy, methyl, ethyl, isopropyl, trifluoromethyl, phenyl and benzyl; wherein each R^4 and R^5 is attached to its respective ring only at carbon atoms; wherein m is 1 or 2; and n is 1, 2, or 3;

 R^6 and R^7 are each independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl and phenyl;

or a pharmaceutically acceptable salt or solvate thereof.

 (New) A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 25 in association with a carrier, diluent and/or excipient.